Skip to content
Peptide research

IGF-1 LR3

Also known as Long R3 IGF-1
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A long-acting analog of IGF-1 marketed for muscle growth, fat loss, and recovery. Extended activity is documented, but growth and repair claims rest mainly on animal and mechanism studies; human evidence is minimal and safety data are largely absent. Hypoglycemia is common and sometimes fatal with insulin, and its growth-signaling effects raise a real, unresolved cancer concern. Not an approved drug in the US; supply consists of unregulated products sold online.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Enhanced muscle protein synthesis and hyperplasia

    Low

    Stimulates muscle cell proliferation in culture, but animal growth studies show no consistent benefit.

  • Extended biological activity vs native IGF-1

    Medium

    Animal studies confirm reduced IGFBP binding and altered circulation, but no human pharmacokinetic data exists.

  • Improved nutrient partitioning and glucose uptake

    Low

    Lowered glucose and insulin in calves, though the partitioning effect appears weaker than commonly claimed.

Evidence limits

Evidence Level
Preclinical

No human clinical trials have been conducted on IGF-1 LR3 specifically. All evidence comes from animal models (guinea pigs, sheep, mice) and in vitro cell culture studies. Human safety and efficacy data are extrapolated from native IGF-1 clinical studies (mecasermin/Increlex). The compound remains a research reagent without regulatory pathway for human therapeutic use.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    Absolute

    Extended-half-life IGF-1 directly promotes tumor cell proliferation and inhibits apoptosis.

  • Diabetic retinopathy

    High

    Prolonged IGF-1 receptor activation worsens retinal neovascularization.

  • Hypoglycemia-prone individuals

    High

    IGF-1 LR3 can cause severe hypoglycemia. The duration of glucose lowering in humans is unestablished.

  • Organ enlargement risk (high-dose/prolonged use)

    Moderate

    Chronic supraphysiological IGF-1 can cause visceral organ enlargement (heart, kidneys, intestines).

Risk summary(10)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Hypoglycemia (low blood sugar) - most common acute side effect, reported at virtually all dose levels; risk dramatically increased when combined with insulin, with fatalities reported

    High
  • Potential cancer acceleration - promotes cell growth and inhibits apoptosis; one observational study linked higher endogenous IGF-1 to increased all-cancer mortality in older men; it did not measure LR3 risk

    Moderate
  • Insulin resistance with chronic use - frequent use can push the body toward insulin resistance, creating long-term metabolic complications

    Theoretical
  • Fluid retention and edema - water retention is a commonly reported side effect

    Low
  • Joint pain and stiffness - musculoskeletal discomfort is frequently reported

    Moderate
  • Acromegaly-like changes with prolonged use - potential for bone and soft tissue overgrowth with long-term exposure

    Low
  • Endocrine disruption - suppression of natural growth hormone and IGF-1 production via negative feedback

    Moderate
  • No human clinical trial safety data - all safety information is extrapolated from animal studies and native IGF-1 human data

    High
  • Unregulated product quality - unregulated products sold online are not made to pharmaceutical manufacturing standards (GMP); contamination and dosing inaccuracies are possible

    High
  • Headaches and nausea - commonly reported at various dose levels

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.